文献速递前列腺增生与排尿功能障碍

膀胱内注射阿伯肉毒毒素A(Dysport)主动管理膀胱过度活动症症状的疗效——一项前瞻性研究

Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms-A Prospective Study.
PubMed 文献 · Urology · 2019-04-25

该前瞻性研究评估了9年间对难治性特发性逼尿肌过度活动患者采用阿伯肉毒毒素A(Dysport)膀胱内注射主动管理方案的效果,共纳入170例患者、299次治疗。治疗后膀胱过度活动症症状评分(OABSS)和生活质量指数分别平均改善35%和41%(均P<.001),65%的病例OABSS改善≥2分,26%的急迫性尿失禁完全消失,44%的尿失禁严重程度减轻,18.2%的病例因残余尿量高需新发自我导尿。作者认为该治疗安全且高度有效,症状评分改善和自我导尿率与onabotulinumtoxinA相似。

要点

  • 阿伯肉毒毒素A膀胱内注射可使难治性OAB患者OABSS平均改善35%、生活质量指数平均改善41%(均P<.001)。
  • 65%的病例OABSS改善≥2分,26%的急迫性尿失禁完全消失,44%的尿失禁严重程度减轻。
  • 18.2%的病例因残余尿量高需新发自我导尿,作者认为该治疗安全且高度有效。

核心结论

  • 作者认为阿伯肉毒毒素A是难治性OAB症状安全且高度有效的治疗选择。
  • 作者数据显示,在症状评分改善和自我导尿率方面,阿伯肉毒毒素A与onabotulinumtoxinA的结果相似。

研究设计与样本

  • 前瞻性研究,回顾了连续接受阿伯肉毒毒素A膀胱内注射治疗的OAB患者数据,这些患者为经尿动力学证实的特发性逼尿肌过度活动、且最大剂量药物治疗和膀胱训练失败者。
  • 共分析170例患者的299次治疗,治疗前及治疗后6周复查时完成OABSS和Likhart生活质量指数。
  • 在全身麻醉下注射阿伯肉毒毒素A 250单位,仅在恢复药物治疗联合膀胱训练失败后才提供重复治疗。

主要发现

  • OABSS平均改善35%(P<.001),生活质量指数平均改善41%(P<.001)。
  • 65%的病例OABSS改善2分或以上。
  • 26%的病例急迫性尿失禁完全消失,44%的病例尿失禁严重程度减轻。
  • 药物治疗在平均10.2个月后恢复,重复阿伯肉毒毒素A注射治疗之间的平均间隔为21.3个月。
  • 18.2%的病例因残余尿量高需新发自我导尿。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present the results our active management protocol for bothersome overactive bladder (OAB) symptoms using abobotulinumtoxinA (Dysport) over a 9-year period. MATERIAL AND METHODS: Data from consecutive patients with OAB symptoms due to urodynamically-proven idiopathic detrusor overactivity who had failed maximum-dose pharmacotherapy and bladder drill were reviewed. All patients completed the Overactive Bladder Symptom Score (OABSS) and Likhart quality of life indices before treatment and again at review 6 weeks post-treatment. Two hundred and fifty units of abobotulinumtoxinA were injected under general anaesthesia. Repeat treatment was offered only after failed resumption of pharmacotherapy with bladder drill. RESULTS: The results of 299 treatments in 170 patients were reviewed. OABSS and quality of life indices improved by a mean of 35% (P ˂.001) and 41% (P ˂.001), respectively, with the OABSS improving by 2 or more points in 65% of cases. While urgency incontinence was completely abolished in 26%, the severity of incontinence was reduced in 44%. Pharmacotherapy was resumed after a mean of 10.2 months, and the mean interval between repeat abobotulinumtoxinA injection treatments was 21.3 months. De-novo self-catheterization was required in 18.2% of cases due to high postvoid residuals. CONCLUSION: The use of abobotulinumtoxinA is safe and highly effective treatment option for patients with refractory OAB symptoms. Our data show similar outcomes to onabotulinumtoxinA in terms of symptom score improvement and self-catheterization rates.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Craciun M, Irwin PP. Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms-A Prospective Study. Urology. 2019. PMID: 31029669. doi:10.1016/j.urology.2019.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。